ACET
Adicet Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.53
−0.88%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$4.70
From 52W high−71.40%
Volume228437.00
Market cap$42.41M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$4.70
From 52W high
−71.40%
Volume
228437.00
Market cap
$42.41M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.7x
P/E (TTM)
—
RSI (14)
25.3
MomentumView details →
1D Return
−0.88%
YTD Return
−46.50%
SummaryUpdated Jun 1, 2026
Adicet Bio, Inc. (NASDAQ:ACET) is a clinical-stage biotechnology company founded in 2014 and based in Boston, Massachusetts. The company went public in January 2018 and specializes in developing innovative cancer immunotherapies using genetically engineered immune cells. Adicet focuses specifically on gamma delta T cell therapies, representing a novel approach in the rapidly evolving field of cellular immunotherapy for treating various cancers and potentially other diseases.
Similar companies
Latest newsMore news →
No recent news for ACET.